Immunobiotic lactobacilli reduce viral-associated pulmonary damage through the modulation of inflammation–coagulation interactions

Zelaya, Hortensia; Tsukida, Kohichiro; Chiba, Eriko; Marranzino, Gabriela; Álvarez, Susana; Kitazawa, Haruki; Agüero, Graciela; Villena, Julio

doi:10.1016/j.intimp.2013.12.020

Cited by 61 publications

(95 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are in line with previous reports of our group using this strain in the context of pulmonary infections with other pathogens [11,21,38,39]. The delicate balance between pro-inflammatory cytokines and anti-inflammatory cytokines is pivotal for a proper and regulated immune response.…”

Section: Discussionsupporting

confidence: 92%

“…To study the systemic hemostasis, we evaluated some parameters such as global coagulation tests, von Willebrand factor (vWF) in plasma, and platelet counts in blood. Challenge with poly(I:C) significantly decreased prothrombin activity in the control group, as we demonstrated previously [11], however, Lr1505 and HK-Lr1505 treatments induced an improvement of this parameter (Fig. 8).…”

Section: Pro-coagulant State Induced By Poly(i:c) Mimics Ifv Infectiosupporting

confidence: 85%

“…As we demonstrated previously [11], poly(I:C) induced a clear tissue inflammation around alveoli and blood vessels in lung, with a significant reduction of gas exchange space in some regions of lungs (Fig. 7).…”

Section: Lung Inflammation and Injury Induced By Poly(i:c) Resembles supporting

confidence: 83%

“…In addition, we unraveled the key role of enhanced interleukin (IL)-10 production in resolving inflammation and limiting lung injury, which was strain-specific. This was the first report showing that an orally administered LAB strain modulated the coagulation state triggered by viral infections [11].…”

Section: Introductionmentioning

confidence: 91%

“…We recently reported that viable Lactobacillus rhamnosus CRL1505 (Lr1505) in contrast to L. rhamnosus CRL1506 administered orally, was able to protect mice from respiratory syncytial virus (RSV) and IFV challenges [11]. We showed that the early induction of pro-inflammatory cytokines accompanied by an increase in antiviral interferon (IFN)-c, were responsible for the increased survival to both respiratory viruses tested.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Nasal priming with immunobiotic Lactobacillus rhamnosus modulates inflammation–coagulation interactions and reduces influenza virus-associated pulmonary damage

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Pro-coagulant State Induced By Poly(i:c) Mimics Ifv Infectiosupporting

confidence: 85%

Section: Lung Inflammation and Injury Induced By Poly(i:c) Resembles supporting

confidence: 83%

Section: Introductionmentioning

confidence: 91%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Nasal priming with immunobiotic Lactobacillus rhamnosus modulates inflammation–coagulation interactions and reduces influenza virus-associated pulmonary damage

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

Effects of a honeybee lactic acid bacterial microbiome on human nasal symptoms, commensals, and biomarkers

Mårtensson

Greiff

Lamei

et al. 2016

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

show abstract

Designer probiotics: Opening the new horizon in diagnosis and prevention of human diseases

Debnath,

Yadav,

Mehta

et al. 2023

Biotech & Bioengineering

View full text Add to dashboard Cite

Probiotic microorganisms have been used for therapeutic purposes for over a century, and recent advances in biotechnology and genetic engineering have opened up new possibilities for developing therapeutic approaches using indigenous probiotic microorganisms. Diseases are often related to metabolic and immunological factors, which play a critical role in their onset. With the help of advanced genetic tools, probiotics can be modified to produce or secrete important therapeutic peptides directly into mucosal sites, increasing their effectiveness. One potential approach to enhancing human health is through the use of designer probiotics, which possess immunogenic characteristics. These genetically engineered probiotics hold promise in providing novel therapeutic options. In addition to their immunogenic properties, designer probiotics can also be equipped with sensors and genetic circuits, enabling them to detect a range of diseases with remarkable precision. Such capabilities may significantly advance disease diagnosis and management. Furthermore, designer probiotics have the potential to be used in diagnostic applications, offering a less invasive and more cost‐effective alternative to conventional diagnostic techniques. This review offers an overview of the different functional aspects of the designer probiotics and their effectiveness on different diseases and also, we have emphasized their limitations and future implications. A comprehensive understanding of these functional attributes may pave the way for new avenues of prevention and the development of effective therapies for a range of diseases.

show abstract

Immunobiotic lactobacilli reduce viral-associated pulmonary damage through the modulation of inflammation–coagulation interactions

Cited by 61 publications

References 42 publications

Nasal priming with immunobiotic Lactobacillus rhamnosus modulates inflammation–coagulation interactions and reduces influenza virus-associated pulmonary damage

Nasal priming with immunobiotic Lactobacillus rhamnosus modulates inflammation–coagulation interactions and reduces influenza virus-associated pulmonary damage

Effects of a honeybee lactic acid bacterial microbiome on human nasal symptoms, commensals, and biomarkers

Designer probiotics: Opening the new horizon in diagnosis and prevention of human diseases

Contact Info

Product

Resources

About